Astena Holdings Co., Ltd.
8095・Prime Market・Wholesale Trade
Business
Astena Holdings Co., Ltd. traces its origins to a long-established company founded in 1914, and transitioned to a holding company structure in June 2021. The company is composed of 27 subsidiaries and 1 affiliated company, centered on four business segments: Fine Chemicals (pharmaceutical CMC outsourcing, CDMO, and raw material supply), HBC & Food (cosmetics and food ingredient sales, cosmetics manufacturing and sales), Pharmaceuticals (generic drugs and aesthetic medical products), and Chemicals (surface treatment chemicals and equipment for the electronics industry). Its main customers span a wide range, including pharmaceutical manufacturers, ventures, electronic components manufacturers, and cosmetics manufacturers, and the company is listed on the Prime Market of the Tokyo Stock Exchange. It is currently pursuing its mid- to long-term vision "Astena 2030," targeting net sales of ¥90.0 billion or more (on a post-revenue recognition standard basis) and ROE of 13.0% or more in FY2030 (ending November 2030).
Business Model
In the Fine Chemicals and HBC & Food Business, the company positions itself as an industry platformer, offering a broad range of products and services, and aims to create added value by deepening client relationships and accumulating information through customer problem-solving. In the Pharmaceutical Business and Chemicals Business, the company narrows its target markets and aims for niche-top positions through differentiation based on proprietary technologies (such as Molecular Hiving™ and Surface Treatment Technologies). It diversifies revenue sources across contract manufacturing, raw material sales, product sales, equipment sales, and maintenance, while simultaneously pursuing segment expansion through M&A.
Company Strengths
In FY2025 (ending November 2025), the API manufacturing field of the Pharmaceutical CDMO division recorded a record-high volume of high-value-added contract items handled. The introduction of a two-shift system for external preparation manufacturing improved production capacity, and both sales and profit trended favorably. Operating profit for the Fine Chemicals Business as a whole reached ¥909 million, up 314.5% year on year.
Leveraging the peptide synthesis method Molecular Hiving™ held by JITSUBO Co., Ltd., orders for process development projects for mid-molecule APIs grew from overseas global mega pharma companies and others. Against the backdrop of expanding demand for the development of mid-molecule pharmaceuticals (peptides and nucleic acids), competitiveness in the global market continues to strengthen.
In the Cosmetics Manufacturing & Sales Division, sales increased significantly due to the effect of new product launches in the imported Korean cosmetics series "Torriden." Sales for the HBC & Food Business as a whole reached ¥18,190 million (up 20.0% year on year), and operating profit was ¥700 million (up 12.4% year on year), recording the highest sales growth rate among all segments.
ENVALITH's Perspective
Performance Trend
Revenue bottomed out at ¥49,636 million in FY2022 and has grown for four consecutive periods since. In H1 FY2026 (ending November 2026), revenue reached ¥34,566 million (up 14.8% year on year), accelerating further, driven by the consolidation effect of the Ikeda Bussan Group (HBC & Food Business up 41.7%) and rapid expansion in the Chemicals Business (up 33.1%). Operating profit rose to ¥2,294 million (up 3.2% year on year), maintaining a growth trend, though PMI costs in HBC & Food and a decline in Fine Chemicals profit capped further upside. The full-year forecast remains unchanged, with revenue of ¥68,000 million (up 8.4% year on year) and operating profit of ¥3,400 million (up 12.6% year on year). As an external factor, expanding investment in generative AI is boosting the Chemicals Business, while raw material cost increase risk stemming from the Middle East situation remains a source of uncertainty for the second half. The equity ratio improved to 38.0% (versus 35.7% at the end of the previous period).
Growth Strategy
Under the Astena 2030 Vision, the company is pursuing three strategies aimed at achieving net sales of ¥90 billion or more and ROE of 13% or higher
Against a backdrop of active investment in package substrate-related areas driven by the expansion of the generative AI market, the company is pursuing new customer acquisition in China and expanded sales of chemicals for passive components. In the first half of FY2026 (ending March 2026), operating profit reached ¥606 million (up 218.3% year on year), and full-year revenue contribution is expected.
Regarding the Ikeda Bussan Group, consolidated in September 2025, the provisional accounting treatment for the business combination was finalized in the current interim period (goodwill of ¥511 million and customer-related assets of ¥1,269 million were recognized). Temporary PMI costs are currently being incurred, and the next challenge is to improve profitability through cost reduction and realization of synergies following the completion of PMI.
In the Pharmaceutical CDMO (Formulation & API Contract Manufacturing) segment, the company has secured contract work for clinical trial drugs and testing in the formulation manufacturing field, but the decline in large-volume items in the raw material manufacturing field is continuing. Expansion of mid-sized molecule API process development projects utilizing Molecular Hiving™ technology is progressing, and recovery of orders in the CMC field will be key to the second half.
In the Social Impact Business based in the Okunoto region of Ishikawa Prefecture, net sales increased 107.2% year on year, driven by expanded adoption of "Furusato NOW" by new municipalities and strengthened sales promotion in the healthcare segment. Operating loss narrowed to ¥128 million (compared with a loss of ¥202 million in the same period of the previous year), continuing the trend of loss reduction.
Last updated: July 17, 2026